Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Invion ( (AU:IVX) ).
Invion Limited, the ASX-listed life-science company developing Photosoft-based next generation photodynamic therapy for cancer and infectious diseases, is expanding its international profile through a series of conference appearances. The company’s Executive Chair and CEO, Professor Thian Chew, will present at major regional industry events including BIONNOVA 2026 in Shanghai and Bio Korea 2026, underscoring Invion’s efforts to showcase its technology to global partners and investors.
These presentations are expected to highlight the potential of Invion’s Photosoft platform as an affordable precision medicine option with broad therapeutic reach and minimal side effects. By engaging with stakeholders at these conferences, Invion aims to strengthen its industry positioning, attract strategic interest, and advance commercial and clinical opportunities for its next generation photodynamic therapy programs.
More about Invion
Invion Limited is an Australian life-science company listed on the ASX that focuses on developing its proprietary Photosoft technology as a next generation photodynamic therapy. The company is targeting a range of cancers, atherosclerosis and infectious diseases, including antibiotic-resistant superbugs, positioning its platform as a less invasive alternative to surgery with potential broad-spectrum applications.
Average Trading Volume: 79,546
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.82M
See more insights into IVX stock on TipRanks’ Stock Analysis page.